| 今开：0.0 | 昨收：0.44 |
| 最高：0.0 | 最低：0.0 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：6050304.0 |
chuminhua2021-03-16 17:53
3月15日，新型抗生素研发公司MelintaTherapeutics宣布美国FDA已批准其Kimyrsa（oritavancin），用于治疗由指定革兰氏阳性微生物的敏感分离株（包括耐甲氧西林金黄色葡萄球菌，MRSA）引起的急性细菌性皮肤和皮肤结构感染（ABSSSI）成人患者。Kimyrsa是一种糖肽类抗生素，1小时单剂输注1200 mg就可提...查看全文
医药魔方2019-12-31 09:21
继今年上半年开发抗生素的上市公司Achaogen申请破产之后，另外一家专注开发新型抗生素的上市公司Melinta Therapeutics也在近日按照《美国破产法典》第11章程序申请破产。
Melinta是Cempra制药公司的继承实体。Cempra制药公司位于北卡罗来纳州教堂山市，于2005年11月18日成立，是一家开发抗细菌...查看全文
用户48783635432019-04-10 11:18
【4月9日医药股盘点】$Histogenics(HSGX)$$PhaseBio制药(PHAS)$ $Melinta Therapeutics(MLNT)$ 细胞疗法公司Histogenics同制药公司Ocugen合并，上涨56%；制药公司PhaseBio Pharmaceuticals上涨17.15%；抗生素开发公司Melinta Therapeutics上涨15.15%等。查看全文网页链接查看全文
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-12-19 AccNo: 0001193125-18-353219 Size: 121 KBItem 1.01: Entry into a Material Definitive AgreementItem 1.02: Termination of a Material Definitive AgreementItem 2.03: Creation of a Direct Financial Obligation...
$Melinta Therapeutics, Inc.(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-10 AccNo: 0001193125-18-346070 Size: 66 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ DEF 14A - Other definitive proxy statements Filed: 2018-11-29 AccNo: 0001193125-18-338188 Size: 994 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2018-11-21 AccNo: 0001193125-18-332441 Size: 84 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-11-19 AccNo: 0001193125-18-330433 Size: 167 KBItem 1.01: Entry into a Material Definitive AgreementItem 3.02: Unregistered Sales of Equity SecuritiesItem 9.01: Financial Statements and Exhibits 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ PRE 14A - Other preliminary proxy statements Filed: 2018-11-19 AccNo: 0001193125-18-330412 Size: 1 MB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-11-19 AccNo: 0001193125-18-330433 Size: 167 KBItem 1.01: Entry into a Material Definitive AgreementItem 3.02: Unregistered Sales of Equity SecuritiesItem 9.01: Financial Statements and Exhibits 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ PRE 14A - Other preliminary proxy statements Filed: 2018-11-19 AccNo: 0001193125-18-330412 Size: 1 MB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2018-11-16 AccNo: 0001193125-18-329055 Size: 36 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-11-16 AccNo: 0001193125-18-329044 Size: 76 KB 网页链接